

1 **TITLE**

2 Severe COVID-19 is associated with fungal colonization of the nasopharynx and potent induction of IL-17
3 responses in the nasal epithelium

4
5 **AUTHORS**

6 Carly G. K. Ziegler^{1,2,3,4,5,*}, Anna H. Owings^{6,*}, Vincent N. Miao^{1,2,3,5}, Andrew W. Navia^{2,3,5,7}, Ying Tang⁸,
7 Joshua D. Bromley^{2,3,5,9}, Peter Lotfy^{3,8}, Meredith Sloan⁶, Hannah Laird¹⁰, Haley B. Williams¹⁰, Micayla
8 George^{2,3,5}, Riley S. Drake^{2,3,5}, Yilianys Pride¹⁰, George E. Abraham III¹¹, Michal Senitko¹¹, Tanya O.
9 Robinson¹⁰, Michail S. Lionakis¹², Alex K. Shalek^{1,2,3,4,5,7,13,14,15,^}, Jose Ordovas-Montanes^{2,3,8,14,15,^}, Bruce
10 H. Horwitz^{8,14,16,^}, Sarah C. Glover^{10,17,^}

11
12 **AFFILIATIONS**

13 ¹ Program in Health Sciences & Technology, Harvard Medical School & MIT, Boston, MA, USA

14 ² Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA

15 ³ Broad Institute of MIT and Harvard, Cambridge, MA, USA

16 ⁴ Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA, USA

17 ⁵ Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA

18 ⁶ Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

19 ⁷ Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA

20 ⁸ Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA, USA

21 ⁹ Department of Microbiology, Massachusetts Institute of Technology, Cambridge, MA, USA

22 ¹⁰ Division of Digestive Diseases, University of Mississippi Medical Center, Jackson, MS, USA

23 ¹¹ Division of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi Medical Center, Jackson, MS, USA

24 ¹² Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and
25 Infectious Diseases (NIAID), Bethesda, MD, USA

26 ¹³ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

27 ¹⁴ Program in Immunology, Harvard Medical School, Boston, MA, USA

28 ¹⁵ Harvard Stem Cell Institute, Cambridge, MA, USA

29 ¹⁶ Division of Emergency Medicine, Boston Children's Hospital, Boston, MA, USA

30 ¹⁷ Center for Immunology and Microbial Research, Department of Cell & Molecular Biology, University of Mississippi Medical Center,
31 Jackson, MS, USA

32 * these authors contributed equally

33 ^ these senior authors contributed equally

34
35 Correspondence to: Jose Ordovas-Montanes (jose.ordovas-montanes@childrens.harvard.edu), Bruce H. Horwitz

36 (bruce.horwitz@childrens.harvard.edu), Sarah C. Glover (scglover@umc.edu), and Alex K. Shalek (shalek@mit.edu)

37 **ABSTRACT**

38 Recent case reports and epidemiological data suggest fungal infections represent an under-appreciated
39 complication among people with severe COVID-19. However, the frequency of fungal colonization in
40 patients with COVID-19 and associations with specific immune responses in the airways remain
41 incompletely defined. We previously generated a single-cell RNA-sequencing (scRNA-seq) dataset
42 characterizing the upper respiratory microenvironment during COVID-19, and mapped the relationship
43 between disease severity and the local behavior of nasal epithelial cells and infiltrating immune cells. Our
44 study, in agreement with findings from related human cohorts, demonstrated that a profound deficiency in
45 host immunity, particularly in type I and type III interferon signaling in the upper respiratory tract, is
46 associated with rapid progression to severe disease and worse clinical outcomes. We have now performed
47 further analysis of this cohort and identified a subset of participants with severe COVID-19 and concurrent
48 detection of *Candida* species-derived transcripts within samples collected from the nasopharynx and
49 trachea. Here, we present the clinical characteristics of these individuals, including confirmatory diagnostic
50 testing demonstrating elevated serum (1, 3)- β -D-glucan and/or confirmed fungal culture of the predicted
51 pathogen. Using matched single-cell transcriptomic profiles of these individuals' respiratory mucosa, we
52 identify epithelial immune signatures suggestive of IL-17 stimulation and anti-fungal immunity. Further, we
53 observe significant expression of anti-fungal inflammatory cascades in the nasal and tracheal epithelium of
54 all participants who went on to develop severe COVID-19, even among participants without detectable
55 genetic material from fungal pathogens. Together, our data suggests that IL-17 stimulation – in part driven
56 by *Candida* colonization – and blunted type I/III interferon signaling represents a common feature of severe
57 COVID-19 infection.

58
59
60
61
62
63
64
65
66
67
68
69
70
71

72 **KEYWORDS:** SARS-CoV-2, COVID-19, human, nasal mucosa, epithelial immunity, *Candida*, fungal
73 infection, IL-17, cytokine, interferon, anti-viral, scRNA-seq

74 **INTRODUCTION**

75 Infection with SARS-CoV-2, the virus that causes COVID-19, can lead to severe viral pneumonitis and the
76 development of acute respiratory distress syndrome.^{1,2} Severe COVID-19 is characterized by peripheral
77 immune dysregulation, and we and others, have previously demonstrated blunted interferon responses
78 within the nasal mucosa of patients with severe COVID-19.^{3–5} Recent case reports and retrospective cohort
79 studies suggest secondary infection with fungal pathogens may be a significant contributor to morbidity and
80 mortality in patients with severe COVID-19.^{6–11} The frequency of fungal colonization of the airways in
81 patients with severe COVID-19 and potential impact on local mucosal immunity remains unknown.^{9,12–15} IL-
82 17, released by CD4 T cells and innate lymphocytes, is a key effector cytokine that coordinates mucosal
83 anti-fungal immunity among other adaptive and innate leukocytes, granulocytes, and mucosal stroma.^{16–19}
84 Recent work has uncovered complex interactions between IL17-driven inflammation, type 1 interferon
85 responses, and susceptibility to fungal pathogens, however the effect of fungal colonization and anti-fungal
86 immune responses during co-occurrent SARS-CoV-2 infection have yet to be explored²⁰. Here, using a
87 previously-published dataset derived from a cohort of individuals acutely infected with SARS-CoV-2, we
88 directly assessed co-occurrent fungal colonization in the airways of patients with severe COVID-19 and
89 examine pathways associated with anti-fungal immunity.³

90

91 **RESULTS**

92 We had previously described a cohort of 58 individuals – 56 of which are further characterized here –
93 including 15 healthy participants, 35 individuals diagnosed with acute COVID-19, and 6 intubated patients
94 that were negative for SARS-CoV-2.³ Nasopharyngeal (NP) swabs obtained from these patients were
95 employed in a cross-sectional study of the nasal respiratory cellular composition using single-cell RNA
96 sequencing (scRNA-seq) (**Figure 1A, 1B**). Patients in this cohort with COVID-19 were sampled within 9
97 days of hospital admission (median: hospital day 2), which we estimated was within 2 weeks of initial
98 respiratory symptoms. Full cohort demographic data and findings relating to the cellular composition,
99 behaviors, and response to SARS-CoV-2 infection between disease groups can be found in our prior
100 manuscript. We had previously applied a meta-transcriptomic taxonomic classification analysis to each
101 sample to assign both cell-associated and ambient/extracellular sequencing reads to a reference database
102 of human and microbial genomes (generated on 5/5/2020 from the NCBI Reference Sequence Database
103 including archaeal, bacterial, viral, protozoan, and fungal genomes).^{21,22} This approach, in addition to direct
104 reference-based alignment, enabled us to quantify respiratory abundances of SARS-CoV-2, and connect
105 viral abundances to the cellular sources of viral replication, as well as concurrent epithelial host responses
106 (**Figure 1B**). Here, we describe further analysis of the data generated from these nasopharyngeal samples,
107 as well as additional data generated from matched endotracheal aspirates (ETA) obtained from 4 of the
108 individuals in the original cohort with severe COVID-19.

109

110 Using meta-transcriptomic alignment of scRNA-seq data, we identified additional high-abundance microbial
111 taxa across healthy participants and those with COVID-19 including common commensal microbes such
112 as *Cutibacterium acnes*, *Malassezia restricta*, and *Staphylococcus aureus* (**Supplemental Figure 1A**,
113 **Supplemental Table 1**). After SARS-CoV-2, the second-most abundant microbe detected was *Candida*
114 *albicans*, which was detected on six NP samples obtained from patients with severe COVID-19 (**Figures**
115 **1C, 1D, Supplemental Figure 1A**). We also identified high levels of *Candida glabrata* in NP samples from
116 2 patients with severe COVID-19, and *Candida dubliniensis* in 4 samples. All samples that were positive
117 for *C. glabrata* or *C. dubliniensis* were also positive for *C. albicans* with the exception of the NP sample
118 obtained from COVID-19 participant 12. *Candida albicans* was also detected in 3 of 4 ETA samples
119 obtained from patients with severe COVID-19. For one patient (COVID-19 participant 32) *C. albicans* was
120 detected via ETA, but was not detected on their matched NP swab. All 3 ETA samples that were positive
121 for *C. albicans* were also positive for *C. dubliniensis*, and one of these was also positive for *C. glabrata*
122 (**Figures 1C, 1D, and Supplemental Figures 1A, 1B**). Notably, no *Candida spp.* or other fungal pathogens
123 were detected within samples obtained from healthy individuals, those obtained from individuals with
124 mild/moderate COVID-19, or those obtained from SARS-CoV-2 negative intubated patients in the intensive
125 care unit with severe respiratory failure due to alternative causes. Thus, all *Candida spp.* reads were
126 detected among patients who developed severe COVID-19 requiring intubation and mechanical ventilation
127 (WHO severity score of 6-8).

128
129 Nearly all NP or ETA samples that were positive for *Candida spp.* were collected within one week of hospital
130 admission (**Supplemental Figure 2A**). The majority (6/8) had been intubated for at least 1 day and 5/8 had
131 received at least 1 day of corticosteroid treatment prior to sample collection. Clinical evaluations during
132 hospitalization were performed to search for possible fungal infection for 3 of the 8 patients with high
133 abundances of *Candida spp.* by meta-transcriptomic classification. COVID-19 participant 12, who had high
134 abundance of *Candida glabrata* RNA sampled by NP swab on hospital day 2, was intubated on hospital
135 day 1 and ETA fungal cultures sampled on hospital day 2 revealed growth of *Candida glabrata* (**Figure 1D**).
136 For two participants, detection of *Candida spp.*-derived RNA via NP/ETA sampling significantly preceded
137 clinical diagnostic testing for fungal pathogens. COVID-19 participant 38, whose NP swab revealed both
138 *Candida albicans* and *Candida dubliniensis* RNA on hospital day 8, tested positive for serum (1,3)- β -D-
139 glucan on hospital day 14 and had *Candida albicans* growth from ETA culture on hospital day 16. Both the
140 NP and ETA samples from COVID-19 participant 18 obtained on hospital day 6 contained high abundances
141 of reads classified as *C. albicans*, and *C. dubliniensis* was detected in the ETA sample. On hospital day 12,
142 (1,3)- β -D-glucan was detected in this individual's serum, prompting treatment with micafungin (an
143 echinocandin antifungal).²³ Together, this demonstrates that for a subset of patients, there was significant
144 clinical concern during their hospitalization to prompt additional testing to evaluate for *Candida* respiratory
145 infection or fungemia. Among those individuals, we find concordance between detection of *Candida* derived
146 RNA from scRNA-seq libraries and clinical assays during their hospitalization.

147

148 We did not detect a difference in demographics or clinical characteristics – apart from severity of COVID-
149 19 – between patients whose samples did or did not contain *Candida*-specific reads (**Table 1,**
150 **Supplemental Figure 2B-2G**). 28-day mortality rates among individuals with severe COVID-19 were
151 similar between *Candida spp.* positive vs. negative groups: 62.5% (5/8) among participants with *Candida*
152 *spp.* detected, compared to 84.6% (11/13) among participants without *Candida spp.* detected. Nearly all
153 (7/8) participants with COVID-19 whose samples contained *Candida spp.*-aligning RNA were previously
154 diagnosed with type 2 diabetes mellitus (T2DM), and 8/8 were diagnosed with chronic hypertension.
155 Notably, although T2DM represents an independent risk factor for mucosal *Candida* colonization, we did
156 not find *Candida* or other fungal species among individuals with T2DM within the Healthy, non-COVID-19
157 intubated, or COVID-19 mild/moderate groups.²⁴ Additionally, for individuals with recently measured
158 HbA1c, we did not identify significant differences in the degree of glycemic control between individuals with
159 different COVID-19 severity or by detection of *Candida*-specific reads (**Supplemental Figure 2G**).²⁵
160 Critically, this analysis is based on a limited sample size, and merits further investigation with adequately-
161 powered cohorts.

162

163 Given the high frequency of *Candida spp.* colonization and clinically-relevant infection among individuals
164 who developed severe COVID-19, we wondered whether the nasal mucosa of these individuals exhibits
165 evidence for reactive or aberrant IL-17 responses. To better define the response of the human nasal
166 epithelium to IL-17 we reanalyzed our previously-published population RNA-seq data which reflects gene
167 expression in human nasal epithelial cells following *in vitro* exposure to a range of doses of IL17A
168 (**Supplemental Figure 3**).^{26,27} Across multiple human donors, IL17A exposure led to upregulation of genes
169 involved in keratinization (*SPRR2E*, *SPRR2F*, and *SPRR2G*), chemoattractant cytokines for lymphocytes,
170 monocytes, and neutrophils (*CCL20*, *CXCL1*, *CXCL2*, and *CXCL3*), and pro-inflammatory factors such as
171 *S100A7* and *S100A8* (**Figure 2A, Supplemental Figure 3A**).^{28–30} IL17A additionally resulted in dose-
172 dependent induction of serum amyloid A genes *SAA1* and *SAA2* from nasal epithelial cells, which has
173 previously been linked to pathogenic Th17 responses at barrier tissues.³¹

174

175 Using this RNA-seq data, we generated consensus gene sets for each tested cytokine that were robust
176 across distinct donors, thereby giving us cell-type specific gene expression modules for IL17A, IFN α , IFN γ ,
177 IL1 β , and IL4 (**Supplemental Figure 3, Supplemental Table 2**). Next, we returned to the scRNA-seq data
178 from our human COVID-19 cohort and evaluated epithelial cells for transcriptomic signatures consistent
179 with exposure to each cytokine. Compared to epithelial cells isolated from healthy controls, epithelial cells
180 isolated from individuals with severe COVID-19 expressed significantly higher levels of genes that were
181 also induced by IL17A exposure *in vitro* (**Figures 2B-D, Supplemental Figure 3B**). In particular, IL17A-
182 induced genes *SAA1*, *SAA2*, *SAT1*, *LCN2*, *S100A8*, and *GLUL* were repeatedly significantly upregulated
183 among diverse epithelial cell subsets in severe COVID-19, but were not found to be significantly induced

184 within the nasal epithelia of patients with milder COVID-19. We confirmed that treatment of nasal epithelial
185 cells with other inflammatory signals potentially found within the respiratory epithelium, including IL4 and
186 IL1 β , do not appreciably induce these factors, suggesting that induction of this gene module is a specific
187 downstream effect of IL17 sensing (**Supplemental Figure 3C**).

188
189 Next, we directly scored epithelial cells for expression of gene signatures indicative of IL17A, IFN α , or IFN γ .
190 (**Figures 2E-G**). Individuals who developed severe COVID-19 expressed consistently higher abundances
191 of IL17A-induced genes compared to healthy participants or those with mild/moderate COVID-19 (**Figure**
192 **2E**). Interestingly, we did not detect higher abundances of genes in the IL17A gene module among
193 participants with severe COVID-19 and detectable *Candida spp.* compared to participants with severe
194 COVID-19 without detectable fungal pathogens. Likewise, we did not detect significant differences in levels
195 of interferon-induced signatures between individuals with and without *Candida spp.* detected (**Figures 2F,**
196 **2G**). On an individual level, participants whose nasal epithelial cells expressed higher abundances of IFN α -
197 induced genes did not express IL17A-induced genes, and vice versa (**Figure 2H**). Together, this suggests
198 that induction of IL17A-stimulated genes in the nasal epithelium represents a shared feature of individuals
199 who develop severe COVID-19, and is correlated with the absence of robust interferon-induced anti-viral
200 responses.

201

202

203 **DISCUSSION**

204 Our data demonstrate *Candida spp.* colonization of the upper respiratory tract in a significant proportion
205 (38%) of individuals hospitalized with severe COVID-19 in a cohort from the University of Mississippi
206 Medical Center sampled during the summer 2020 COVID-19 peak. Notably, no fungal pathogens were
207 identified among individuals with mild or moderate COVID-19, non-COVID-19 ICU patients, or healthy
208 controls. Fungal reads were detected by NP swab at early timepoints following hospital admission and
209 within the acute phase of patients COVID-19 disease trajectory, suggesting that in some patients, fungal
210 colonization and infection likely occurred prior to hospital admission and in advance of nosocomial
211 exposures. *Candida* is not typically present in the nares of healthy people, being more readily detected in
212 the oropharynx, thus identification of *Candida* from NP swabs of a subset of patients with severe COVID-
213 19 would suggest either that severe COVID-19 predisposes to ectopic colonization in some hosts, or
214 alternatively that our methodology is detecting increased fungal abundances derived from the oral
215 mucosa³². Further direct comparisons of colonization in the mouth and nose of patients with severe COVID-
216 19 will be necessary to clarify this issue.³³

217

218 Our analysis additionally unites the use of single-cell transcriptomic technologies in human clinical cohorts
219 with emerging computational approaches for meta-genomic pathogen classification of human samples, all
220 derived from limited cellular material captured on a single NP swab^{21,22}. By linking unbiased pathogen

221 detection with single-cell nasal epithelial and immune transcriptional profiles, we have identified specific
222 host behaviors indicative of response to a fungal pathogen and IL-17 signaling. For a subset of patients,
223 early detection of *Candida spp.* in the upper respiratory mucosa corresponded to development of more
224 extensive colonization and clinical concern for secondary fungal pneumonia and/or candidemia. Mounting
225 evidence across various clinical cohorts, including our prior work, suggests that severe COVID-19 arises in
226 individuals with impaired anti-viral immunity.^{3,34-41} While there is a paucity of evidence to suggest that type
227 I/III interferon signaling directly restricts fungal colonization, prior *in vitro* studies indicate IL-17 signaling
228 among airway epithelial cells may attenuate cellular responses to type I/III interferon^{20,42-45}. Additionally,
229 enhanced virally-induced epithelial injury resulting from impaired IFN signaling could facilitate *Candida*
230 colonization.^{46,47} Surprisingly, we observe that IL17A-induced gene sets are elevated among epithelial cells
231 from *all* individuals with severe COVID-19 in our cohort, even those patients without genomic or clinical
232 evidence for co-incident fungal infection. Crucially, our data does not allow us to determine whether our
233 observation of elevated IL-17 responses in patients with severe COVID-19 *without* overt evidence for fungal
234 colonization is 1) the result of colonization below levels of detection in these assays, or 2) suggest that IL17
235 elevation represents a general phenotype of epithelial cells of patients with severe COVID-19, independent
236 of fungal colonization. Future experiments encompassing longitudinal sampling of patients with COVID-19
237 could shed additional light on whether variability in the dynamics of IL-17 and interferon signaling may
238 underlie *Candida* colonization in the upper airways.

239
240 Together, our data suggests upper respiratory *Candida* colonization and infection represents an
241 underappreciated phenomenon among patients with severe COVID-19. Further research with larger
242 cohorts is warranted to understand the frequency and timing of co-occurring infection with *Candida spp.*
243 and other fungal pathogens following SARS-CoV-2 infection. Further, our data suggests that dedicated,
244 multi-institutional studies are required to disentangle how clinical and subclinical fungal infections impact
245 patient outcomes during hospitalization for COVID-19, and may hold key insights into determinants of
246 severe respiratory failure for these patients and new strategies for diagnostic or therapeutic intervention.

247 **ACKNOWLEDGEMENTS**

248 We thank the study participants and their families for enabling this research, the clinical support staff at
249 UMMC for assistance in sample collection, and the members of the Shalek, Ordovas-Montanes, Horwitz,
250 and Glover labs for thoughtful discussion and comments on the project. This project has been made
251 possible in part by grant number 2020-216949 from the Chan Zuckerberg Initiative DAF, an advised fund
252 of Silicon Valley Community Foundation to A.K.S. and J.O.M.. C.G.K.Z. was supported by award number
253 T32GM007753 and T32GM144273 from the National Institute of General Medical Sciences. J.O.M is a New
254 York Stem Cell Foundation – Robertson Investigator. J.O.M was supported by the Richard and Susan Smith
255 Family Foundation, the AGA Research Foundation’s AGA-Takeda Pharmaceuticals Research Scholar
256 Award in IBD – AGA2020-13-01, the HDDC Pilot and Feasibility P30 DK034854, the Food Allergy Science
257 Initiative, the Leona M. and Harry B. Helmsley Charitable Trust, The Pew Charitable Trusts Biomedical
258 Scholars, The Broad Next Generation Award, The Chan Zuckerberg Initiative Pediatric Networks, The
259 Mathers Foundation, The New York Stem Cell Foundation, and The Manton Foundation Cell Discovery
260 Network at Boston Children’s Hospital. B.H.H. was supported by DK122532-01A1, NIH; 12019PG-CD002,
261 The Leona M. and Harry B. Helmsley Charitable Trust; SRA #54518, and Crohn’s and Colitis Foundation.
262 A.K.S. was supported by the Bill and Melinda Gates Foundation, Sloan Fellowship in Chemistry, the NIH
263 (5U24AI118672), and the Ragon Institute of MGH, MIT and Harvard. This work was supported in part by
264 the Division of Intramural Research of the NIAID.

265

266 **AUTHOR CONTRIBUTIONS**

267 Conceptualization: J.O.-M., A.K.S., S.C.G., B.H.H.
268 Methodology: C.G.K.Z., A.H.O., S.C.G., J.O.-M., A.K.S., B.H.H.
269 Formal analysis: C.G.K.Z., A.H.O.
270 Investigation: C.G.K.Z., A.H.O.
271 Resources: S.C.G., A.H.O., M.SI., H.L., A.P., C.B.S., M.W.B., M.Se., M.H., G.E.A.
272 Data Curation: T.O.R., Y.T., M.SI. A.H.O., H.L., H.B.W., T.C., C.G.K.Z.
273 Writing – Original Draft: C.G.K.Z., A.H.O., J.O.-M., A.K.S., S.C.G., B.H.H.
274 Writing – Review & Editing: C.G.K.Z., V.N.M., A.H.O., A.W.N., Y.T., J.D.B., P.L., M.SI., H.L., H.B.W., M.G.,
275 R.S.D., T.C., A.P., C.B.S., M.W.B., Y.P., M.H., G.E.A., M.Se., T.O.R., A.K.S., S.C.G., B.H.H., J.O.-M.
276 Visualization: C.G.K.Z.
277 Supervision: J.O.-M., A.K.S., S.C.G., B.H.H., T.O.R.
278 Project Administration: Y.P., T.O.R.
279 Funding Acquisition: J.O.-M., A.K.S., S.C.G., B.H.H.

280

281 **COMPETING INTERESTS**

282 A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb
283 Biotechnologies, Cellarity, Repertoire Immune Medicines, Hovione, Ochre Bio, Third Rock Ventures, FL82,

284 Empress Therapeutics, Senda Biosciences, IntrECate Biotherapeutics, Relation Therapeutics, and Dahlia
285 Biosciences. J.O.M. reports compensation for consulting services with Cellarity and Hovione.

286 METHODS

287

288 Participant Recruitment and Respiratory Sampling

289 Full participant characteristics are provided in previously published study³. The UMMC Institutional Review
290 Board approved the study under IRB#2020-0065. All participants or their legally authorized representative
291 provided written informed consent. Briefly, participants were eligible for inclusion in the COVID-19 group if
292 they were at least 18 years old, had a positive nasopharyngeal swab for SARS-CoV-2 by PCR, had COVID-
293 19 related symptoms including fever, chills, cough, shortness of breath, and sore throat, and weighed more
294 than 110 lb. Participants were eligible for inclusion in the Healthy group if they were at least 18 years old,
295 had a current negative SARS-CoV-2 test (PCR or rapid antigen test), and weighed more than 110 lb.
296 COVID-19 participants were classified according to the 8-level ordinal scale proposed by the WHO
297 representing their peak clinical severity and level of respiratory support required. Nasopharyngeal samples
298 and endotracheal aspirate samples were collected by a trained healthcare provider, all processing and
299 handling was carried out as previously described.^{3,26}

300

301 scRNA-seq Data Generation and Alignment

302 Annotated scRNA-seq data was recovered from Single Cell Portal (see **Data Availability** below) and single
303 cell annotations were used as described in Ziegler et al. *Cell* 2021. Briefly, data represent aligned scRNA-
304 seq libraries generated using Seq-Well S³, libraries were generated using Illumina Nextera XT Library Prep
305 Kits and sequenced on NextSeq 500/550 High Output 75 cycle v2.5 kits to an average depth of 180 million
306 aligned reads per array: read 1: 21 (cell barcode, UMI), read 2: 50 (digital gene expression), index 1: 8
307 (N700 barcode).⁴⁸ Libraries were aligned using STAR within the Drop-Seq Computational Protocol
308 (<https://github.com/broadinstitute/Drop-seq>) and implemented on Cumulus
309 (https://cumulus.readthedocs.io/en/latest/drop_seq.html, snapshot 9, default parameters).^{49,50} As
310 previously described, data were aligned using a custom reference which combined human GRCh38 (from
311 Cell Ranger version 3.0.0, Ensembl 93) and SARS-CoV-2 RNA genomes.^{3,51}

312

313 Meta-Transcriptomic Pathogen Classification

314 To identify co-detected microbial taxa present in the cell-associated or ambient RNA of nasopharyngeal
315 swabs, we used the Kraken2 software implemented using the Broad Institute viral-ngs pipelines on Terra
316 (<https://github.com/broadinstitute/viral-pipelines/tree/master>).^{21,22} A previously-published reference
317 database included human, archaea, bacteria, plasmid, viral, fungi, and protozoa species and was
318 constructed on May 5, 2020, therefore included sequences belonging to the novel SARS-CoV-2 virus.
319 Inputs to Kraken2 were: `kraken2_db_tgz = "gs://pathogen-public-dbs/v1/kraken2-broad-20200505.tar.zst"`,
320 `krona_taxonomy_db_kraken2_tgz = "gs://pathogen-public-dbs/v1/krona.taxonomy-20200505.tab.zst"`,
321 `ncbi_taxdump_tgz = "gs://pathogen-public-dbs/v1/taxdump-20200505.tar.gz"`, `trim_clip_db =`
322 `"gs://pathogen-public-dbs/v0/contaminants.clip_db.fasta"` and `spikein_db = "gs://pathogen-public-`

323 dbs/v0/ERCC_96_nopolyA.fasta". Results were collected using the merge_metagenomics tool
324 (https://viral-pipelines.readthedocs.io/en/latest/merge_metagenomics.html), and analysis and visualization
325 of each samples' metagenomic alignments was implemented in Prism (v6) or R (v4.0.2; packages ggplot2
326 (v3.3.2), Seurat (v3.2.2), ComplexHeatmap (v2.7.3)). All classification data is included as **Supplemental**
327 **Table 1**.

328

329 **Human Nasal Epithelial Cell Response to *In Vitro* Cytokine Exposure**

330 Gene lists representing human nasal epithelial cell responses to various exogenous cytokines *in vitro* are
331 derived from a previously-published population RNA-seq data.^{26,27} Briefly, human nasal epithelial basal
332 cells from 2 donors were stimulated *in vitro* with 0.1-10 ng/mL IFN α , IL17A, IFN γ , IL1 β , or IL4 for 12 hours.
333 Following stimulation, cells were lysed and bulk RNA-seq libraries were generated using the SMART-Seq2
334 protocol.⁵² We identified epithelial gene sets induced by each cytokine independently by testing for
335 differentially expressed genes compared to matched, untreated nasal epithelial samples (n=10). Differential
336 expression testing was carried out using a likelihood ratio test assuming a negative binomial distribution,
337 implemented with the Seurat (v3.1.5) FindAllMarkers function (test.use = "negbinom"). We considered
338 genes as differentially expressed with an FDR-adjusted p value < 0.05.⁵³

339

340 To score for cytokine-specific gene expression among COVID-19 or Healthy scRNA-seq samples, we first
341 subsetted our scRNA-seq data to only epithelial cells using "Coarse" cell types, as defined by cell typing
342 procedure carried out in prior publication (Ziegler et al. *Cell* 2021). Coarse cell type groups that were
343 included in the analysis: "Ciliated Cells", "Developing Ciliated Cells", "Secretory Cells", "Goblet Cells",
344 "Ionocytes", "Deuterosomal Cells", "Squamous Cells", "Basal Cells", "Mitotic Basal Cells", and "Developing
345 Secretory and Goblet Cells". We calculated module scores over all epithelial cells using the Seurat function
346 AddModuleScore with default inputs. The average module score for each NP or ETA sample was utilized
347 as a representative measure of epithelial behavior for each participant, as represented in **Figures 2E-2H**.

348

349 **scRNA-seq Analysis of Differential Expression**

350 To compare gene expression between cells from distinct disease groups (e.g. Healthy vs. Severe COVID-
351 19, *Candida spp.*), we employed a likelihood ratio test assuming a negative binomial distribution as
352 described above (using Seurat FindAllMarkers function (test.use = "negbinom")).⁵³ We considered genes
353 as differentially expressed with an FDR-adjusted p value < 0.001 and log fold change > 0.25. Results from
354 select "Detailed" cell types, as defined and previously reported by Ziegler et al. are represented in **Figures**
355 **2B-D**.³ Full results of differential expression as represented in **Figures 2B-D** can be found in Supplementary
356 Tables accompanying the published dataset.

357

358 **Statistical Testing**

359 All statistical tests were implemented in R (v4.0.2) or Prism (v6) software. Specific statistical tests, p-values,

360 n, and all summary statistics are provided in the results section, figure legends, and/or figure panels.

361

362 **Data Availability**

363 All scRNA-seq and RNA-seq data analyzed in this study is publicly available from prior manuscripts. Aligned
364 and annotated scRNA-seq data can be downloaded via the Single Cell Portal, study SCP1289
365 (https://singlecell.broadinstitute.org/single_cell/study/SCP1289). Aligned TPM-normalized RNA-seq data
366 can be downloaded via the Single Cell Portal, study SCP822
367 (https://singlecell.broadinstitute.org/single_cell/study/SCP822). Results from Kraken2 meta-genomic
368 classification are reported in **Supplemental Table 1**.

369 **MAIN FIGURE TITLES AND LEGENDS**

370

371 **Figure 1. Co-detection of host single-cell transcriptome with intracellular and microenvironmental**
372 **pathogen-derived genomic material**

373 **A.** Schematic of biological sample processing pipeline

374 **B.** Schematic of computational pipeline for each sample

375 **C.** Abundance of human, SARS-CoV-2, and *Candida spp.* by participant and disease group as defined
376 by meta-transcriptomic classification. N=56 participants. Lines represent median +/- interquartile
377 range.

378 **D.** Summary of results from sequencing, fungal culture, and serum (1,3)- β -D-glucan assays from 8
379 participants with detectable *Candida* species reads by nasopharyngeal swab or endotracheal
380 aspirate.

381 **Figure 2. Respiratory epithelial transcriptional signatures following *in vitro* IL17A stimulation and**
382 ***in vivo* fungal colonization in a severe COVID-19 cohort**

383 **A.** Heatmap of population RNA-seq data comparing untreated nasal epithelial cells to those treated
384 with increasing concentrations of IL17A as indicated across columns. Genes (rows) with significant
385 differential expression between untreated and IL17A-treated conditions (FDR-corrected $p < 0.05$).

386 **B.-D.** Volcano plots of differentially expressed genes between select epithelial cell types from healthy
387 participants vs. those with severe COVID-19: developing ciliated cells (**B**), *CCL5*^{high} squamous cells
388 (**C**), and early response *FOXJ1*^{high} ciliated cells (**D**). Grey points: all genes. Black points: genes
389 induced in human nasal epithelial cells following IL17A treatment (as in **Figure 2A**).

390 **E.-G.** Average gene module scores calculated for each participant, separated by disease group.
391 Module score expression was computed over all epithelial cells. Input module genes derived from
392 *in vitro* stimulation with each labeled cytokine: IL17A (**E**), IFN α (**F**), IFN γ (**G**). Statistical testing by
393 Kruskal-Wallis test with Dunn's post-hoc testing. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$. Lines
394 represent mean \pm SEM.

395 **H.** Average gene module scores by participant, IFN α module on x-axis, IL17A module on y-axis. Points
396 only reflecting NP samples. Point shapes and colors by disease group: Healthy: dark blue circles;
397 Mild/Moderate COVID-19: red circles; Severe COVID-19, *Candida spp.* neg.: pink filled squares;
398 Severe COVID-19, *Candida spp.* pos.: pink outlined squares. Statistical testing by Spearman's
399 correlation over all points: $\rho = 0.43$, ** $p = 0.0018$.

400 **MAIN TABLE TITLE AND LEGEND**

401

402 **Table 1. Demographics and medical comorbidities of patients with severe COVID-19**

403 **SUPPLEMENTAL FIGURE TITLES AND LEGENDS**

404

405 **Supplemental Figure 1. Meta-transcriptomic classification of reads from nasopharyngeal swabs and**
406 **endotracheal aspirates**

407 **A.** Heatmap of top detected microbes (rows) across all samples (columns). Bar plot on left: total
408 classified reads per million (M) for each microbe listed along heatmap rows. Heatmap colors
409 represent total classified reads per M, dark red: higher abundance, yellow: lower abundance, white:
410 < 10 reads per M.

411 **B.** SARS-CoV-2 and *Candida spp.* reads detected from matched nasopharyngeal (NP, black bars)
412 and endotracheal aspirate (ETA, grey bars) samples from the same participants.

413 **Supplemental Figure 2. Participant characteristics and clinical course**

414 **A.** Hospital timelines for 8 participants with *Candida spp.* detected from scRNA-seq NP or ETA
415 samples.

416 **B.-D.** Select categorical demographic and clinical information from study participants by disease cohort:
417 28-day mortality (**B**), type 2 diabetes mellitus (T2DM) (**C**), and chronic hypertension (**D**). Statistical
418 testing by multi-group chi-square test, significance result is reported above each plot.

419 **E.-F.** Select continuous demographic and clinical information among participants with severe COVID-
420 19, separated by detection of *Candida spp.*: age (**E**) and BMI (**F**). Statistical testing using student's
421 t-test. Lines represent median +/- interquartile range.

422 **G.** Hemoglobin A1c (HbA1c) for each study participant by disease cohort. Dashed line at HbA1c 6.5%.
423 Group differences non-significant by Kruskal-Wallis test. Numbers in parenthesis reflect patients
424 per group with available data in medical record.

425 **Supplemental Figure 3. Transcriptional responses of respiratory epithelial cells following *in vitro***
426 **exposure to various cytokines**

427 **A.** Expression of select genes following 12-hour stimulation with increasing doses of IL17A. Each
428 gene significantly upregulated following IL17A expression by likelihood ratio test, FDR-adjusted p-
429 value < 0.001. Lines represent mean +/- SEM.

430 **B.** Heatmap of IL17A-induced genes among developing ciliated cells from NP swabs. Heatmap colors
431 reflect scaled gene expression: red: higher expression, blue: lower expression. Left columns (blue
432 bar): developing ciliated cells from n=15 Healthy participants; right (pink bar): developing ciliated
433 cells from n=8 participants with severe COVID-19 and *Candida spp.* detected. Genes (rows)
434 selected represent genes significantly upregulated among cultured human nasal epithelia cells
435 following *in vitro* exposure to IL17A. Statistical significance comparing Healthy-derived vs. Severe
436 COVID-19, *Candida spp.* positive-derived single cells by likelihood ratio test assuming an
437 underlying negative binomial distribution. *** FDR-corrected p < 0.001, ** FDR < 0.01, * FDR <
438 0.05.

439 **C.** Expression of select genes among human nasal basal cells by stimulation condition.

440 **SUPPLEMENTAL TABLES TITLES**

441

442 **Supplemental Table 1. Raw meta-transcriptomic classification data from Kraken2**

443

444 **Supplemental Table 2. Gene lists for scoring epithelial responses to cytokines**

445 **REFERENCES**

- 446
- 447 1. Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D.S.C., et al.
- 448 (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of*
- 449 *Medicine* 382, 1708–1720.
- 450 [10.1056/NEJMOA2002032/SUPPL_FILE/NEJMOA2002032_DISCLOSURES.PDF](https://doi.org/10.1056/NEJMOA2002032/SUPPL_FILE/NEJMOA2002032_DISCLOSURES.PDF).
- 451 2. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al.
- 452 (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The*
- 453 *Lancet* 395, 497–506. [10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 454 3. Ziegler, C.G.K., Miao, V.N., Owings, A.H., Navia, A.W., Tang, Y., Bromley, J.D., Lotfy, P., Sloan,
- 455 M., Laird, H., Williams, H.B., et al. (2021). Impaired local intrinsic immunity to SARS-CoV-2
- 456 infection in severe COVID-19. *Cell* 184, 4713–4733.e22. [10.1016/J.CELL.2021.07.023](https://doi.org/10.1016/J.CELL.2021.07.023).
- 457 4. Yoshida, M., Worlock, K.B., Huang, N., Lindeboom, R.G.H., Butler, C.R., Kumasaka, N.,
- 458 Dominguez Conde, C., Mamanova, L., Bolt, L., Richardson, L., et al. (2021). Local and systemic
- 459 responses to SARS-CoV-2 infection in children and adults. *Nature* 2021 602:7896 602, 321–327.
- 460 [10.1038/s41586-021-04345-x](https://doi.org/10.1038/s41586-021-04345-x).
- 461 5. Chua, R.L., Lukassen, S., Trump, S., Hennig, B.P., Wendisch, D., Pott, F., Debnath, O.,
- 462 Thürmann, L., Kurth, F., Völker, M.T., et al. (2020). COVID-19 severity correlates with airway
- 463 epithelium–immune cell interactions identified by single-cell analysis. *Nature Biotechnology* 2020
- 464 38:8 38, 970–979. [10.1038/s41587-020-0602-4](https://doi.org/10.1038/s41587-020-0602-4).
- 465 6. Hassan, I., Powell, G., Sidhu, M., Hart, W.M., and Denning, D.W. (2009). Excess mortality, length
- 466 of stay and cost attributable to candidaemia. *J Infect* 59, 360–365. [10.1016/J.JINF.2009.08.020](https://doi.org/10.1016/J.JINF.2009.08.020).
- 467 7. Kayaaslan, B., Eser, F., Kaya Kalem, A., Bilgic, Z., Asilturk, D., Hasanoglu, I., Ayhan, M., Tezer
- 468 Tekce, Y., Erdem, D., Turan, S., et al. (2021). Characteristics of candidemia in COVID-19 patients;
- 469 increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19
- 470 patients. *Mycoses* 64, 1083–1091. [10.1111/MYC.13332](https://doi.org/10.1111/MYC.13332).
- 471 8. Chumbita, M., Puerta-Alcalde, P., Garcia-Pouton, N., and García-Vidal, C. (2021). COVID-19 and
- 472 fungal infections: Etiopathogenesis and therapeutic implications. *Rev Esp Quimioter* 34 *Suppl* 1,
- 473 72–75. [10.37201/REQ/S01.21.2021](https://doi.org/10.37201/REQ/S01.21.2021).
- 474 9. Garcia-Vidal, C., Sanjuan, G., Moreno-García, E., Puerta-Alcalde, P., Garcia-Pouton, N.,
- 475 Chumbita, M., Fernandez-Pittol, M., Pitart, C., Inciarte, A., Bodro, M., et al. (2021). Incidence of
- 476 co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort
- 477 study. *Clin Microbiol Infect* 27, 83–88. [10.1016/J.CMI.2020.07.041](https://doi.org/10.1016/J.CMI.2020.07.041).
- 478 10. Arastehfar, A., Carvalho, A., Hong Nguyen, M., Hedayati, M.T., Netea, M.G., Perlin, D.S., and
- 479 Hoenigl, M. (2020). COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in
- 480 the Absence of Immunological Predispositions? *J Fungi (Basel)* 6, 1–13. [10.3390/JOF6040211](https://doi.org/10.3390/JOF6040211).
- 481 11. White, P.L., Dhillon, R., Cordey, A., Hughes, H., Faggian, F., Soni, S., Pandey, M., Whitaker, H.,
- 482 May, A., Morgan, M., et al. (2021). A National Strategy to Diagnose Coronavirus Disease 2019-
- 483 Associated Invasive Fungal Disease in the Intensive Care Unit. *Clin Infect Dis* 73, e1634–e1644.
- 484 [10.1093/CID/CIAA1298](https://doi.org/10.1093/CID/CIAA1298).
- 485 12. Mastrangelo, A., Germinario, B.N., Ferrante, M., Frangi, C., Li Voti, R., Muccini, C., and Ripa, M.
- 486 (2021). Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and
- 487 Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls. *Clin*
- 488 *Infect Dis* 73, E2838–E2839. [10.1093/CID/CIAA1594](https://doi.org/10.1093/CID/CIAA1594).
- 489 13. Nucci, M., Barreiros, G., Guimarães, L.F., Deriquehem, V.A.S., Castiñeiras, A.C., and Nouér, S.A.
- 490 (2021). Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic.
- 491 *Mycoses* 64, 152–156. [10.1111/MYC.13225](https://doi.org/10.1111/MYC.13225).
- 492 14. Omrani, A.S., Koleri, J., ben Abid, F., Daghfel, J., Odaippurath, T., Peediyakkal, M.Z., Baiou, A.,
- 493 Sarsak, E., Elayana, M., Kaleeckal, A., et al. (2021). Clinical characteristics and risk factors for
- 494 COVID-19-associated Candidemia. *Med Mycol* 59, 1262–1266. [10.1093/MMY/MYAB056](https://doi.org/10.1093/MMY/MYAB056).
- 495 15. Bretagne, S., Sitbon, K., Botterel, F., Dellièrre, S., Letscher-Bru, V., Chouaki, T., Bellanger, A.-P.,
- 496 Bonnal, C., Fekkar, A., Persat, F., et al. (2021). COVID-19-Associated Pulmonary Aspergillosis,
- 497 Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter
- 498 Observational Cohort during the First French Pandemic Wave. *Microbiol Spectr* 9.
- 499 [10.1128/SPECTRUM.01138-21](https://doi.org/10.1128/SPECTRUM.01138-21).

- 500 16. Sparber, F., and Leibundgut-Landmann, S. (2019). Interleukin-17 in Antifungal Immunity.
501 *Pathogens* 8, 54. 10.3390/PATHOGENS8020054.
- 502 17. Mengesha, B.G., and Conti, H.R. (2017). The Role of IL-17 in Protection against Mucosal Candida
503 Infections. *Journal of Fungi* 3. 10.3390/JOF3040052.
- 504 18. Puel, A., Cypowyj, S., Maródi, L., Abel, L., Picard, C., and Casanova, J.L. (2012). Inborn errors of
505 human IL-17 immunity underlie chronic mucocutaneous candidiasis. *Curr Opin Allergy Clin*
506 *Immunol* 12, 616. 10.1097/ACI.0B013E328358CC0B.
- 507 19. Trautwein-Weidner, K., Gladiator, A., Nur, S., Diethelm, P., and Leibundgut-Landmann, S. (2015).
508 IL-17-mediated antifungal defense in the oral mucosa is independent of neutrophils. *Mucosal*
509 *Immunol* 8, 221–231. 10.1038/MI.2014.57.
- 510 20. Break, T.J., Oikonomou, V., Dutzan, N., Desai, J. v., Swidergall, M., Freiwald, T., Chauss, D.,
511 Harrison, O.J., Alejo, J., Williams, D.W., et al. (2021). Aberrant type 1 immunity drives
512 susceptibility to mucosal fungal infections. *Science* (1979) 371.
513 10.1126/SCIENCE.AAY5731/SUPPL_FILE/AAY5731_TABLE-S4.XLSX.
- 514 21. Lemieux, J.E., Siddle, K.J., Shaw, B.M., Loreth, C., Schaffner, S.F., Gladden-Young, A., Adams,
515 G., Fink, T., Tomkins-Tinch, C.H., Krasilnikova, L.A., et al. (2020). Phylogenetic analysis of SARS-
516 CoV-2 in Boston highlights the impact of superspreading events. *Science* (1979).
517 10.1126/science.abe3261.
- 518 22. Wood, D.E., Lu, J., and Langmead, B. (2019). Improved metagenomic analysis with Kraken 2.
519 *Genome Biol.* 10.1186/s13059-019-1891-0.
- 520 23. Wiederhold, N.P., Cota, J.M., and Frei, C.R. (2008). Micafungin in the treatment of invasive
521 candidiasis and invasive aspergillosis. *Infect Drug Resist* 1, 63.
- 522 24. Bader, M.S., Lai, S.M., Kumar, V., and Hinthorn, D. (2004). Candidemia in patients with diabetes
523 mellitus: epidemiology and predictors of mortality. *Scand J Infect Dis* 36, 860–864.
524 10.1080/00365540410021126.
- 525 25. Rodrigues, C.F., Rodrigues, M.E., and Henriques, M. (2019). Candida sp. Infections in Patients
526 with Diabetes Mellitus. *J Clin Med* 8. 10.3390/JCM8010076.
- 527 26. Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K., Buchheit, K.M., Vukovic, M., Deb, C.,
528 Wadsworth, M.H., Hughes, T.K., Kazer, S.W., Yoshimoto, E., et al. (2018). Allergic inflammatory
529 memory in human respiratory epithelial progenitor cells. *Nature*. 10.1038/s41586-018-0449-8.
- 530 27. Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbanjo, I.M., Miao, V.N., Tzouanas, C.N., Cao, Y.,
531 Yousif, A.S., Bals, J., Hauser, B.M., et al. (2020). SARS-CoV-2 Receptor ACE2 Is an Interferon-
532 Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across
533 Tissues. *Cell*. 10.1016/j.cell.2020.04.035.
- 534 28. Cabral, A., Voskamp, P., Cleton-Jansen, A.M., South, A., Nizetic, D., and Backendorf, C. (2001).
535 Structural organization and regulation of the small proline-rich family of cornified envelope
536 precursors suggest a role in adaptive barrier function. *J Biol Chem* 276, 19231–19237.
537 10.1074/JBC.M100336200.
- 538 29. Christmann, C., Zenker, S., Martens, L., Hübner, J., Loser, K., Vogl, T., and Roth, J. (2021).
539 Interleukin 17 Promotes Expression of Alarmins S100A8 and S100A9 During the Inflammatory
540 Response of Keratinocytes. *Front Immunol* 11, 3831. 10.3389/FIMMU.2020.599947/BIBTEX.
- 541 30. Sun, D., Novotny, M., Bulek, K., Liu, C., Li, X., and Hamilton, T. (2011). Treatment with IL-17
542 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-
543 regulatory factor SF2 (ASF). *Nat Immunol* 12, 853–860. 10.1038/NI.2081.
- 544 31. Lee, J.Y., Hall, J.A., Kroehling, L., Wu, L., Najjar, T., Nguyen, H.H., Lin, W.Y., Yeung, S.T., Silva,
545 H.M., Li, D., et al. (2020). Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote
546 Inflammatory Disease. *Cell* 180, 79-91.e16. 10.1016/J.CELL.2019.11.026.
- 547 32. Salehi, M., Ahmadikia, K., Mahmoudi, S., Kalantari, S., Jamalimoghadamsiahkali, S., Izadi, A.,
548 Kord, M., Dehghan Manshadi, S.A., Seifi, A., Ghiasvand, F., et al. (2020). Oropharyngeal
549 candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal
550 susceptibility pattern. *Mycoses* 63, 771–778. 10.1111/MYC.13137.
- 551 33. Findley, K., Oh, J., Yang, J., Conlan, S., Deming, C., Meyer, J.A., Schoenfeld, D., Nomicos, E.,
552 Park, M., Becker, J., et al. (2013). Topographic diversity of fungal and bacterial communities in
553 human skin. *Nature* 2013 498:7454 498, 367–370. 10.1038/nature12171.
- 554 34. Galani, I.E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki,
555 E., Fragkou, P.C., Panou, V., Rapti, V., et al. (2021). Untuned antiviral immunity in COVID-19

- 556 revealed by temporal type I/III interferon patterns and flu comparison. *Nat Immunol* 22, 32–40.
557 10.1038/S41590-020-00840-X.
- 558 35. Kusnadi, A., Ramírez-Suástegui, C., Fajardo, V., Chee, S.J., Meckiff, B.J., Simon, H., Pelosi, E.,
559 Seumois, G., Ay, F., Vijayanand, P., et al. (2021). Severely ill COVID-19 patients display impaired
560 exhaustion features in SARS-CoV-2-reactive CD8⁺ T cells. *Sci Immunol* 6.
561 10.1126/SCIIMMUNOL.ABE4782.
- 562 36. Liu, C., Martins, A.J., Lau, W.W., Rachmaninoff, N., Chen, J., Imberti, L., Mostaghimi, D., Fink,
563 D.L., Burbelo, P.D., Dobbs, K., et al. (2021). Time-resolved systems immunology reveals a late
564 juncture linked to fatal COVID-19. *Cell* 184, 1836-1857.e22. 10.1016/J.CELL.2021.02.018.
- 565 37. Bastard, P., Orlova, E., Sozaeva, L., Lévy, R., James, A., Schmitt, M.M., Ochoa, S., Kareva, M.,
566 Rodina, Y., Gervais, A., et al. (2021). Preexisting autoantibodies to type I IFNs underlie critical
567 COVID-19 pneumonia in patients with APS-1. *Journal of Experimental Medicine* 218.
568 10.1084/jem.20210554.
- 569 38. Zhang, Q., Matuozzo, D., le Pen, J., Lee, D., Moens, L., Asano, T., Bohlen, J., Liu, Z., Moncada-
570 Velez, M., Kendir-Demirkol, Y., et al. (2022). Recessive inborn errors of type I IFN immunity in
571 children with COVID-19 pneumonia. *Journal of Experimental Medicine* 219.
572 10.1084/JEM.20220131/213287.
- 573 39. Zhang, Q., Liu, Z., Moncada-Velez, M., Chen, J., Ogishi, M., Bigio, B., Yang, R., Arias, A.A., Zhou,
574 Q., Han, J.E., et al. (2020). Inborn errors of type I IFN immunity in patients with life-threatening
575 COVID-19. *Science* (1979). 10.1126/science.abd4570.
- 576 40. Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.H., Zhang, Y., Dorgham, K.,
577 Philippot, Q., Rosain, J., Béziat, V., et al. (2020). Autoantibodies against type I IFNs in patients
578 with life-threatening COVID-19. *Science* (1979). 10.1126/science.abd4585.
- 579 41. Combes, A.J., Courau, T., Kuhn, N.F., Hu, K.H., Ray, A., Chen, W.S., Chew, N.W., Cleary, S.J.,
580 Kushnoor, D., Reeder, G.C., et al. (2021). Global absence and targeting of protective immune
581 states in severe COVID-19. *Nature*. 10.1038/s41586-021-03234-7.
- 582 42. Espinosa, V., Dutta, O., McElrath, C., Du, P., Chang, Y.J., Cicciarelli, B., Pitler, A., Whitehead, I.,
583 Obar, J.J., Durbin, J.E., et al. (2017). Type III interferon is a critical regulator of innate antifungal
584 immunity. *Sci Immunol* 2. 10.1126/SCIIMMUNOL.AAN5357.
- 585 43. Smeekens, S.P., Ng, A., Kumar, V., Johnson, M.D., Plantinga, T.S., van Diemen, C., Arts, P.,
586 Verwiel, E.T.P., Gresnigt, M.S., Fransen, K., et al. (2013). Functional genomics identifies type I
587 interferon pathway as central for host defense against *Candida albicans*. *Nat Commun* 4.
588 10.1038/NCOMMS2343.
- 589 44. Marié, I.J., Brambilla, L., Azzouz, D., Chen, Z., Baracho, G. v., Arnett, A., Li, H.S., Liu, W.,
590 Cimmino, L., Chattopadhyay, P., et al. (2021). Tonic interferon restricts pathogenic IL-17-driven
591 inflammatory disease via balancing the microbiome. *Elife* 10. 10.7554/ELIFE.68371.
- 592 45. Niwa, M., Fujisawa, T., Mori, K., Yamanaka, K., Yasui, H., Suzuki, Y., Karayama, M., Hozumi, H.,
593 Furuhashi, K., Enomoto, N., et al. (2018). IL-17A Attenuates IFN- λ Expression by Inducing
594 Suppressor of Cytokine Signaling Expression in Airway Epithelium. *J Immunol* 201, 2392–2402.
595 10.4049/JIMMUNOL.1800147.
- 596 46. Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B.,
597 Bondet, V., Chenevier-Gobeaux, C., et al. (2020). Impaired type I interferon activity and
598 inflammatory responses in severe COVID-19 patients. *Science* (1979) 369, 718–724.
599 10.1126/SCIENCE.ABC6027/SUPPL_FILE/ABC6027-HADJADJ-SM.PDF.
- 600 47. Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K., Mao, T.,
601 Oh, J.E., Israelow, B., et al. (2020). Longitudinal analyses reveal immunological misfiring in severe
602 COVID-19. *Nature*. 10.1038/s41586-020-2588-y.
- 603 48. Gierahn, T.M., Wadsworth, M.H., Hughes, T.K., Bryson, B.D., Butler, A., Satija, R., Fortune, S.,
604 Christopher Love, J., and Shalek, A.K. (2017). Seq-Well: Portable, low-cost rna sequencing of
605 single cells at high throughput. *Nat Methods*. 10.1038/nmeth.4179.
- 606 49. Li, B., Gould, J., Yang, Y., Sarkizova, S., Tabaka, M., Ashenberg, O., Rosen, Y., Slyper, M.,
607 Kowalczyk, M.S., Villani, A.C., et al. (2020). Cumulus provides cloud-based data analysis for
608 large-scale single-cell and single-nucleus RNA-seq. *Nat Methods*. 10.1038/s41592-020-0905-x.
- 609 50. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M.,
610 and Gingeras, T.R. (2013). STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics*.
611 10.1093/bioinformatics/bts635.

- 612 51. Delorey, T.M., Ziegler, C.G.K., Heimberg, G., Normand, R., Yang, Y., Segerstolpe, Å.,
613 Abbondanza, D., Fleming, S.J., Subramanian, A., Montoro, D.T., et al. (2021). COVID-19 tissue
614 atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature* 595, 107–113.
615 [10.1038/s41586-021-03570-8](https://doi.org/10.1038/s41586-021-03570-8).
- 616 52. Trombetta, J.J., Gennert, D., Lu, D., Satija, R., Shalek, A.K., and Regev, A. (2014). Preparation of
617 single-cell RNA-Seq libraries for next generation sequencing. *Curr Protoc Mol Biol*.
618 [10.1002/0471142727.mb0422s107](https://doi.org/10.1002/0471142727.mb0422s107).
- 619 53. Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell
620 transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol*.
621 [10.1038/nbt.4096](https://doi.org/10.1038/nbt.4096).
622

Figure 1




Figure 2




Table 1

	COVID-19 severe (WHO score 6-8) <i>Candida spp.</i> negative	COVID-19 severe (WHO score 6-8) <i>Candida spp.</i> positive
Case number	23.2% (13/56)	14.3% (8/56)
Age (years)		
Minimum	28	38
Median (IQR)	63 (49)	57 (54.3)
Maximum	79	84
Sex		
Female	38.5% (5/13)	62.5% (5/8)
Male	61.5% 8/13	37.5% (3/8)
Ethnicity		
Hispanic	7.7% (1/13)	0% (0/13)
Not Hispanic	92.3% (12/13)	100% (13/13)
Race		
Black/African American	53.8% (7/13)	75% (6/8)
White	23.1% (3/13)	25% (2/8)
American Indian	23.1% (3/13)	0% (0/8)
BMI		
Median (IQR)	29.9 (27.8)	37.0 (33.6)
Pre-existing conditions		
Diabetes	61.5% (8/13)	87.5% (7/8)
Chronic kidney disease	15.4% (2/13)	25% (2/8)
Congestive heart failure	7.7% (1/13)	0% (0/8)
Lung disorder	30.1% (4/13)	50% (4/8)
Hypertension *	69.2% (9/13)	100% (8/8)
IBD	0% (0/13)	0% (0/8)
Treatment		
Corticosteroids	61.5% (8/13)	75% (6/8)
Remdesivir	7.7% (1/13)	0% (0/8)
28-day mortality ***	84.6% (11/13)	62.5% (5/8)

IQR: inter-quartile range; BMI: body mass index; IBD: inflammatory bowel disease